Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJohn E. Levine

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports enhanced survival in myelofibrosis patients receiving haploidentical transplants with post-transplant cyclophosphamide, suggesting new options for treatment.

Key Points

  • High two-year overall survival (OS) rate of 73% observed in all myelofibrosis patients post-transplant.
  • Enhanced progression-free survival (PFS) at 66% demonstrates promise for haploidentical and mismatched unrelated donor strategies.
  • Assessment included retrospective study of 65 primary and secondary myelofibrosis patients from 2015 to 2024.
  • Findings indicate significant benefits of using post-transplant cyclophosphamide for graft versus host disease prophylaxis.

Cite This Study

John E. Levine (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d48chttps://doi.org/10.1182/blood-2025-2530
View Full Paper
Ask AI
Bookmark
Share